



JOINT PRESS RELEASE

Page 1/2

Date: October 12, 2017

bionection 2017 first held in Thuringia: State-of-the-art biotech research meets global market leaders in Jena

The central German Partnering Conference 'bionection' will be held for the first time in the German region of Thuringia on October 17–18. This conference for technology transfer in life sciences is being organized at Volksbad Jena by InfectoGnostics Research Campus in conjunction with host biosaxony. Leading global industrial companies such as Alere Technologies, Carl Zeiss Microscopy, IBM, Jenoptik and Karl Storz will be meeting researchers from outstanding public institutions such as Jena University, Jena University Hospital, and a number of Fraunhofer and Leibniz research institutes. The main themes this year are diagnostics, digital medical technology, point-of-care technologies, optics and photonics as well as biomaterials research and plasma technologies.

For the fourth time, bionection will be bringing together scientists, technology transfer experts and innovative growth companies and offering a platform for new cooperation projects and efficient technology transfer. "We're delighted to be taking bionection to Thuringia for the first time. Here in Jena, first-class high-tech development and interdisciplinary research in the life sciences are optimally combined, making this concentration of science the perfect city for the partnering conference," declared André Hofmann, CEO of biosaxony. This industry association for biotech and medical technology in the region of Saxony hosts bionection annually, alternating between Saxony, Thuringia and Saxony-Anhalt.

As the regional organizer, InfectoGnostics Research Campus Jena will be focusing this year on optics and photonics in the life sciences, diagnostics, analytics and precision medicine as well as digital medical technology. The campus concept of this successful public-private partnership is reflected by the make-up of the panels. In addition to major corporations like Carl Zeiss Microscopy, IBM and Karl Storz, papers will be delivered by experts from emerging small and medium-sized companies (oncgnostics, Blink and Miacom Diagnostics) and public research institutions (Jena University, the IKTS Fraunhofer Institute for Ceramic Technologies and Systems, the ENAS Fraunhofer Institute for Electronic Nano Systems, and Ilmenau University of Technology). In addition, a panel discussion will address the question: "What's the potential of central Germany as a biotech location?"

In addition, the Research Alliance Leibniz Health Technologies will hold two panel sessions addressing 'Biomarkers and point-of-care technologies' and 'Biomaterials and plasma medicine'. Specialists from Leibniz institutes from all over Germany will be showing how basic academic research is being developed into concrete technologies that actually help patients. "Research on health technologies is especially dependent on interdisciplinary collaboration between different centers and early discussions with industry. bionection provides the ideal platform for this," said Professor Jürgen Popp,

Pressekontakt:

Christian Döring Öffentlichkeitsarbeit

InfectoGnostics
Forschungscampus Jena e. V.
Zentrum für Angewandte Forschung
Philosophenweg 7
07743 Jena

Telefon: 03641 – 948 391 Telefax: 03641 – 206 044

E-Mail: christian.doering@infectognostics.de

www.infectognostics.de



öffentlich-private Partnerschaft für Innovationen

Gefördert von







JOINT PRESS RELEASE

Page 2/2

Date: October 12, 2017

spokesman of the Leibniz Research Alliance and CEO of InfectoGnostics Research Campus Jena.

Registration for the conference and 1-on-1 partnering open until October 16

With a total of 7 high-profile keynote speeches, over 30 other papers, short pitches and cooperation offers from leading industrial companies and research institutions, bionection will once again be one of this year's foremost central German industry meetings for biotechnology and medical technology. Apart from on the conference days, direct meetings with potential collaboration partners can again be planned in advance. Registration for bionection and the separate 1-on-1 partnering will remain open until October 16. In total, up to 200 delegates are expected to attend.

As in previous years, the first day of bionection 2017 will conclude with the conference party. At this optional evening function, Professor Andreas Stallmach, Director of the Department of Internal Medicine IV at Jena University Hospital, will present a paper on the human microbiome. Later on, this year's Technology Transfer Trophy (T³) will be awarded, and there will be an opportunity for relaxed conversation accompanied by live music in the cozy atmosphere of the historical Jena Volksbad.

Dates: October 17 and 18, 2017

Venue: Volksbad Jena, Knebelstrasse 10, 07743 Jena

Contact: Karolin Beier (project manager)

Email: beier@biosaxony.com // Tel: +49 (0) 351 796 5106

biosaxony e. V. – the host of bionection

bionection is being hosted by biosaxony e. V., the biotechnology/life sciences cluster association for Saxony. Its members represent the various companies, scientific institutions and lobbyists working in biotechnology and related areas of engineering and the material sciences in Saxony. biosaxony's responsibilities include initiating projects between industry and research, pinpointing services and know-how, and highlighting regional expertise in order to support the productive development of these cross-cutting technologies. In 2016, biosaxony was the host BioRegion of the German Biotech Conference in Leipzig and also set up a new department: Section Medical Technology.

www.biosaxony.com

InfectoGnostics Forschungscampus Jena e. V. - the regional organizer of bionection

bionection will be supported this year by InfectoGnostics Research Campus as the regional organizer. Based in Jena, Thuringia's technology hub, InfectoGnostics has networked industry, science and users within a public-private partnership since 2014, enabling solutions in infection research to be quickly transferred from basic research to the market – and thus the patient. www.infectognostics.de